Skip to main content
Canadian Journal of Public Health = Revue Canadienne de Santé Publique logoLink to Canadian Journal of Public Health = Revue Canadienne de Santé Publique
. 2019 Feb 6;110(2):210–215. doi: 10.17269/s41997-019-00180-w

Supervised inhalation is an important part of supervised consumption services

Stacey Bourque 1,, Em M Pijl 2, Erin Mason 1, Jill Manning 1, Takara Motz 1
PMCID: PMC6964381  PMID: 30725386

Abstract

Setting

The first regulated supervised inhalation site (safer smoking room) in North America has opened in Lethbridge, Alberta, as part of a supervised consumption site addressing all routes of consumption. When designing the service, we felt it was important to accommodate not just injection drug use but also inhalation because (1) it is not the method of drug use that kills but the drug itself, (2) all people who use drugs deserve service regardless of their mode of use, and (3) people who use drugs should have the opportunity to use the method with the lowest risk.

Intervention

We received approval from Health Canada to offer supervised inhalation services in addition to supervised injection services. Based on a European model, we worked with a local commercial heating, cooling, and ventilation (HVAC) company to create rooms with ventilation systems that complied with Canadian health and safety regulations.

Outcome

People who use drugs by inhalation have repeatedly told us that they want to use indoors and will do so given the option. Since opening the supervised consumption service at the end of February 2018, the response has been overwhelming and both of the inhalation rooms are constantly in use.

Implications

Supervised inhalation services provide an alternative to public drug use and an opportunity for people who use drugs to engage with harm reduction services. Other supervised consumption services in Canada may also wish to pursue exemptions for this service.

Keywords: Supervised consumption, Drug consumption rooms, Harm reduction, Inhalation, Supervised injection, Opioids, Crystal meth, Street drugs, Illicit drugs

Introduction

The first sanctioned supervised inhalation facility (SIF; or supervised smoking facility, SSF) in North America has opened in Lethbridge, Alberta, as part of a supervised consumption site (SCS) addressing four routes of consumption. Lethbridge is the fourth largest city by population in Alberta, with a population just above 96,000. ARCHES (AIDS Outreach Community Harm Reduction Education Support, formerly Lethbridge HIV Connection) is the harm reduction agency operating in the area since 1986. ARCHES is a well-established provider of support services to individuals living with HIV/AIDS, hepatitis C, and other chronic illnesses, providing extensive community support, targeted prevention, walking outreach, rural outreach, harm reduction supply distribution (including needles, safer inhalation kits, and condoms), clinical nursing services, and more. When the need for supervised consumption services became evident, ARCHES was the obvious service provider, given their longstanding relationships with the population. (In this article, we will use the acronym SSF—supervised smoking facility—to avoid conflation with the acronym SIF, which could refer to either supervised injection or supervised inhalation facility.)

While SSFs have existed in Europe for years (Shannon et al. 2006), there has been some debate about the merit of SSFs and their relative value to people who use drugs and to harm reduction efficacy. Some stakeholders, including Health Canada, had concerns about ventilation, and others felt that there was a lack of evidence that SSFs would reduce HIV or HCV transmission or that those infections were a concern at all for people who smoked illicit drugs (Watson et al. 2013). Furthermore, the general public is largely unaware of SSFs and their benefit, compared to a much greater knowledge of supervised injection facilities (Strike et al. 2016). Even health authorities can fail to see the value in SSFs (Shannon et al. 2006).

The impetus for our pursuit of a federal exemption from Health Canada to accommodate not just injection drug use, but also inhalation, was fourfold. First, people who use drugs have repeatedly told us that they want to use indoors and will do so given the option. Similarly, McNeil et al. (2015), DeBeck et al. (2011), and Watson et al. (2013) found that people who smoke crack or methamphetamine want to do so out of the public eye in a private and safe space, away from law enforcement and social violence. Public stimulant smoking has been associated with risks such as rushed drug use, increased risk of bloodborne infection, pipe sharing, and public injection (Malchy et al. 2008; Voon et al. 2016). This lack of a safe space in Vancouver led to the Vancouver Area Network of Drug Users (VANDU) accommodating an unsanctioned or provisional safer smoking room; the room was a repurposed bathroom and not (at the time of this writing) specifically designed as an inhalation room (McNeil et al. 2015). People who use drugs have also expressed the belief that providing a SSF was one way to decrease publicly discarded crack and methamphetamine paraphernalia (Watson et al. 2013).

The second reason for creating a SSF was our appreciation that it is not the method of drug use itself that directly results in fatalities but rather the drugs themselves. To limit supervised consumption services to injection, therefore, seemed shortsighted. Certainly, injection drug use is associated with higher numbers of overdoses, due to the fact that the drug is injected as a bolus, is not easily titrated by the person using, and is of unknown constitution. And while theoretically it is possible for someone who is smoking a drug to titrate the amount of drug they are getting, this is certainly not always the case, due in part to the inconsistent and often unknown constitution of street drugs. Additionally, cocaine and methamphetamine alter the permeability of the blood–brain barrier (Dietrich 2009; Riley et al. 2017; Sajja et al. 2016), which not only has direct implications for drug impacts (including overdose) and brain pathology, but for increased access of viruses (including HIV) into the brain (Dietrich 2009).

Third, we believed that by offering a SSF we would be able to connect with a wider clientele than only those who use by injection. While injection drug use is well known for its high risk of complications, inhalation also has complications and risks, including increased risk of HIV or hepatitis C (HCV) and other infections, burns and cuts, and cardiovascular and respiratory problems. Providing safe spaces for supervised smoking creates opportunities for harm reduction interventions and health education, and a method of engagement for a population that does not inject. Collins et al. (2005) suggest that prevention programs are desperately needed to reduce the risk of HCV transmission, and that SSFs could play a “critical role in addressing this public health concern” (p. 281). They also indicate that “crack smokers are less responsive to interventions than other drug users” (p. 281) and that effective interventions, including SSFs, must be developed for this subgroup of high-risk individuals. In Vancouver’s unsanctioned SSF, volunteers distribute harm reduction supplies, disrupt pipe-sharing, and provide timely education regarding health risks (McNeil et al. 2015). Peers who are former and even current drug users are a key component in harm reduction education for people who smoke illicit substances in Vancouver (Jozaghi et al. 2016).

Last, to offer supervised consumption services to one subset of people who use drugs and not another seemed to imply that one group deserved service while another did not. We were concerned about the optics of preferential treatment for one mode of use (injection) over less harmful modes (inhalation/smoking). In a Vancouver study of people who smoke crack, McNeil et al. (2015) found that the omission of safer smoking rooms within regulated consumption sites was noted by the affected population. Thus, we were concerned that by valuing injection and excluding inhalation, we would lose the opportunity to encourage—and support—clients changing to less risky modes of use. Certainly, the distribution of safer smoking supplies has been associated with decreased needle use, as people who use drugs have the option to transition to a safer method of drug use (Leonard et al. 2008). However, it is unclear to what degree the SSF will provide a direct mechanism for people to employ less risky modes of drug consumption.

Intervention

Our application to Health Canada for an exemption to offer supervised smoking services, in addition to the more common supervised injection services, was the first of its kind in Canada. In our application, we were required to include the additional policies and procedures relevant to supervised smoking. Policies unique to inhalation included overdose intervention, workplace health and safety, client-to-staff ratio for safe operation, and emergency evacuation procedures. We were also required to articulate the medical and health benefits of supervised inhalation, since the exemption is based on the medical benefits of supervised consumption. Additionally, we needed to show that we were in compliance with all federal, provincial, and municipal smoking legislation. (Because smoking legislation and bylaws are specific to tobacco and tobacco by-products, a safe inhalation facility would technically not contravene existing laws. There are no existing standards for illicit substances, so we worked with Alberta Labour to ensure we were in compliance with relevant codes by the implementation of protections.)

Concurrently with the development of our application we consulted with our clients—people who use drugs—to determine what they wanted in a supervised smoking service. They told us they wanted ARCHES to offer: separate rooms for separate consumption of substances (e.g., crack in one room, opiates in another); a space where they could inhale with others, as drug use is often a social event; an enclosed space for smoking that was medically monitored by staff; and, a space where any drugs can be used, although they did not want cross-contamination to occur between substances. Clients were very interested in having the option to inhale, in addition to other routes of use with which they may have more experience. In a culture of free needle distribution, free pipe distribution is a relatively recent newcomer and we are finding considerable client uptake of smoking as an alternative to injection.

We received approval from Health Canada to offer supervised inhalation (smoking) services in addition to services addressing ingestion, injection and snorting. Based on a European model, we worked with a local commercial heating, cooling, and ventilation (HVAC) company, who worked in consultation with a mechanical engineer, to create rooms with ventilation systems that complied with Canada’s more stringent occupational health and safety regulations and in accordance with building codes for commercial spaces. Furthermore, the system had to comply with provincial tobacco ordinances (Tobacco Reduction Act) and municipal bylaws. Research has indicated that staff safety is a primary concern regarding the implementation of SSFs and as such, high quality ventilation systems are needed (Watson et al. 2013).

The American Society of Heating, Refrigerating and Air-Conditioning Engineers (ASHRAE) Standard 62.1-2016, Ventilation for Acceptable Indoor Air Quality, guided the technical design of the smoking rooms to ensure acceptable air quality and minimal adverse health effects from second hand smoke. These guidelines, while originating in the United States, have also been adopted in Canada. In these guidelines, “acceptable indoor air quality” means “air in which there are no known contaminants at harmful concentrations as determined by cognizant authorities and with which a substantial majority (80% or more) of the people exposed do not express dissatisfaction” (ASHRAE 2016, p. 3). “Environmental tobacco smoke” is defined as “the ‘aged’ and diluted combination of both side-stream smoke (smoke from the lit end of a cigarette or other tobacco product) and exhaled mainstream smoke (smoke that is exhaled by a smoker)” and commonly known as “secondhand smoke” (ASHRAE 2016, p. 4). This definition also includes smoke produced by cannabis, electronic smoking devices, and controlled substances. However, at this time, some contaminants, including crack and methamphetamine, lack guidelines and standards for acceptable concentrations and exposure values (ASHRAE 2016).

The SSF is mechanically ventilated with a balanced exhaust and supply system. Air enters the dedicated space through steel grilles that are washable and structurally robust. The indoor air from the SSF is filtered and discharged to the outside of the building via a rooftop vent, from where it dissipates into the environment. Each smoking room is an independently ventilated negative air pressure room on its own independent ventilation system, to avoid distributing the smoke to any other area of the SCS. The room is overventilated, by spec, with 250 CFM (cubic feet per minute) of air being removed from each smoking room and 125 CFM flowing into each. The calculation of CFM takes into account both the volume of air and the rate at which it moves into or out of an enclosed space. Ventilation systems are connected to an uninterrupted power supply. Air in the consumption site as a whole is replaced over six times per hour and is replaced 15 times per hour in the smoking rooms.

There is an emergency smoke evacuation switch on the wall of the nursing station, so that in the event an emergency situation arises that requires staff intervention, staff can do so without exposure to smoke. When pushed by the attendant, it closes the air intake damper and clears the room of smoke rapidly, by drawing 600 CFM through each room. The smoking rooms are also air conditioned, as they are located in the centre of the building and tend to become quite warm due to a combination of smoking activities, body temperature, and high usage.

Other design considerations came from people who use drugs, including creating separate injection and smoking areas within the same facility, due to the different effects of uppers and downers, exposure to different methods of use, and different behaviours associated with each (Watson et al. 2013). Some people who use drugs would not want to be exposed to seeing others inject, some would be triggered by others’ drug use, and some felt there was a “pecking order” or stigma associated with the preferred route and use (Watson et al. 2013). Additionally, people who smoked drugs wanted to be able to smoke at the same time as another person, so each room can accommodate three people comfortably. In our Lethbridge needs assessment, using the Edmonton Drug Use and Health Survey (Hyshka et al. 2016), we found that three quarters (76.5%) of the 207 survey respondents said they would use a SSF (Pijl et al. 2017). This acceptance rate was similar to Shannon et al. (2006) and DeBeck et al. (2011), but substantially higher than a study by Collins et al. (2005) which found that only 27% of drug users surveyed would use a SSF if one was available. It is not clear why our population differed from that in the Collins et al. (2005) study. Other research reveals that a small subset of people who use drugs do not see the value in a SSF—particularly compared to SIF—because people “can do a toke of crack anywhere” (Watson et al. 2013, p. 159). In other words, it appears that people who use drugs seem to view smoking as more portable and less risky (than injection) and not requiring a place-based intervention, per se.

The supervised inhalation service was promoted through the community consultation process, during our needs assessment, through our other service delivery (including a significant outreach program) and through our ongoing relationships with clients who access our services. Furthermore, people who access our services let others know about this service by word of mouth. As part of a standard intake process, when clients access the SCS, they are asked about the drugs they are planning to use and the route by which they plan to use them. Staff on site can tailor harm reduction instruction to each client.

Outcome

Since opening the supervised consumption service on February 28, 2018, the response has been overwhelming, to the extent that there is a need to increase the number of inhalation rooms to reduce wait times. There were a total of 654 unique clients who attended the site in the first four months of operation. Of these, most were between the ages of 20 and 29 (37.61%) or 30 and 39 (34.71%). More than half were male (58.41%), and 61.31% identified as Indigenous (First Nations, Métis or Inuit) (see Table 1).

Table 1.

Demographics of unique clients (n = 654) to SCS between March and June 2018

Characteristic Number Percentage
Age (in years)
  < 20 29 4.43
  20–29 246 37.61
  30–39 227 34.71
  40–49 105 16.06
  50–59 43 6.57
  60+ 4 0.61
  Total 654 100.0
Gender
  Male 382 58.41
  Female 272 41.59
Ethnicity
  Caucasian 183 27.98
  Indigenous (FNMI) 401 61.31
  Other 70 10.70

FNMI, First Nations, Métis or Inuit

We had 11 overdoses from inhalation in the first four months after opening; seven of these were related to opioids (five of which were treated with oxygen administration and nurse observation, and two of which were reversed using Naloxone) and four were related to methamphetamine, for which there is no antidote. Overdoses due to inhaled (smoked) drugs contributed to 4.2% of the overall overdose rate for the SCS.

In March 2018, the first month of operation, usage by inhalation accounted for 40.6% (967) of client visits. The number of people smoking in the SSF increased in April to 1653, in May to 2184, and in June to 3576. Thus, the numbers of clients utilizing the inhalation space is increasing (see Table 2). When the consumption site first opened, we noticed that almost half of clients (40.6%) were using by inhalation. Looking at usage by client numbers (representing unique clients): in March 2018, 141 of 237 (59.5%) unique clients used the inhalation room at least once; in April, these numbers rose to 219 of 309 (70.9%) unique clients; in May, 260 of 375 (69.3%), and in June, 321 of 457 (70.2%). The number of visits for the inhalation room increases every month (see Table 3). Overall, we have found that individuals who do not use the inhalation room are clients who access the SCS infrequently (i.e., low average number of visits). Our most frequent SCS users use the inhalation room typically a quarter or less of their visits (i.e., are injection drug users who may sometimes decide to smoke rather than inject). Of clients who used the inhalation room, roughly 42% used it for most or all of their SCS visits (75–100% of the time). Substances being consumed by inhalation (smoking) include, in decreasing order of incidences self-reported by people using the site: methamphetamine (84.7% of recorded substances for inhalation), a variety of opiates (5.27%), and crack (rock) (4.3%) (see Table 4).

Table 2.

Frequency of SCS usage by route

Route March 2018 April 2018 May 2018 June 2018
Oral/intranasal 58 (2.4%) 97 (2.0%) 233 (3.2%) 321 (2.8%)
Inhalation 967 (40.6%) 1653 (34.2%) 2184 (30.1%) 3576 (31.0%)
Injection 1358 (57.0%) 3086 (63.8%) 4843 (66.7%) 7651 (66.3%)
Totals 2383 4836 7260 11,548

Statistics indicate number of visits, not number of unique visitors/clients

Table 3.

Unique clients’ SSF visits accounting for overall supervised consumption site (SCS) use during first months of operation in 2018

Visits March April May June
n (%) n (%) n (%) n (%)
1 or more 141 (59.5%) 219 (70.9%) 260 (69.3%) 321 (70.2%)
None 96 (40.5%) 90 (29.1%) 115 (30.7%) 136 (29.8%)
Total SCS clients 237 (100%) 309 (100%) 375 (100%) 457 (100%)

Further detail is available from ARCHES

Table 4.

Incidences of substances being consumed (client self-report)

Substance Inhalation Intranasal/oral IV injection
Opiates 949 (11.3%) 568 (80.1%) 9667 (57.1%)
 Carfentanil 35 7 320
 Fentanyl 106 531 7706
 Heroin 778 7 1455
 Methadone 19 3 13
 Morphine 8 1 79
 Oxycontin/oxycodone 3 19 94
Uppers
 Methamphetamine 6876 (82.0%) 96 (13.5%) 5073 (29.9%)
 Crack/rock 257 (3.1%) 4 14
 Cocaine 6 14 27
Speedballa 23 4 2097 (12.4%)
Cannabis 267 (3.2%) 1 0
Unknown/other 3 22 63
Total 8381 709 16,941

aMethamphetamine and fentanyl

As of May 22, 2018, we expanded operating hours (previously 0900 h to 0200 h) to a 24/7 operation. This expansion was in response to the overwhelming need that resulted in long lineups outside the facility. Pending funding, we would like to add two more smoking rooms as these are also in high demand.

Since the inception of our supervised consumption application, we intended to actively encourage clients to choose safer forms of drug use other than injection as part of moving them down the treatment continuum. This harm reduction goal informs all areas of our practice. Staff make sure clients are aware of other ways to use a drug. They also encourage people who are not able to find a vein for injection, or who do not know how to inject independently, to consider an alternate (and safer) method, such as inhalation. Harm reduction is in all of the staff members’ conversations with clients. Clients who are seeking to move from inhalation to injection meet with staff to discuss the risks associated. An interesting local phenomenon was the widely held belief, among people who use illicit drugs, that opiates could not be smoked—only taken orally or by injection. ARCHES has been instrumental in helping clients switch to inhaling by providing them with the education and equipment they need, so they are not injecting as much.

As for documenting clients transitioning to less risky routes of drug use (i.e., from injection to smoking) at this early stage, we have considerable anecdotal evidence. Patterns are largely dependent on the number of times a client accesses the site in a month (or a year); the provision of equipment and client education to promote smoking over injection; and the approach of the end of the month, which is associated with clients having fewer financial resources and an increased need to “make do” with what little substances they can procure and use. As our data increase with time and client visits, it may be easier to see how many clients are choosing to change.

Conclusion

Supervised inhalation is a promising innovation to assist people who use drugs. These services provide an alternative to public drug use and an opportunity for people who use drugs to engage with harm reduction services.

Acknowledgements

We are grateful for the professional expertise of Mr. Richard Altvater at 4 Seasons Home Comfort.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Footnotes

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Contributor Information

Stacey Bourque, Phone: 403-942-5702, Email: sbourque@lethbridgearches.com.

Em M. Pijl, Phone: 403-332-5232, Email: em.pijl@uleth.ca

References

  1. ASHRAE . Ventilation for acceptable indoor air quality. Atlanta: Author; 2016. [Google Scholar]
  2. Collins, C. L., Kerr, T., Kuyper, L. M., Li, K., Tyndall, M. W., Marsh, D. C., … Wood, E. (2005). Potential uptake and correlates of willingness to use a supervised smoking facility for noninjection illicit drug use. J Urban Health, 82(2), 276–284. 10.1093/jurban/jti051. [DOI] [PMC free article] [PubMed]
  3. DeBeck K, Buxton J, Kerr T, Qi J, Montaner J, Wood E. Public crack cocaine smoking and willingness to use a supervised inhalation facility: Implications for street disorder. Substance Abuse Treatment, Prevention, and Policy. 2011;6:4. doi: 10.1186/1747-597x-6-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Dietrich JB. Alteration of blood-brain barrier function by methamphetamine and cocaine. Cell & Tissue Research. 2009;336(3):385–392. doi: 10.1007/s00441-009-0777-y. [DOI] [PubMed] [Google Scholar]
  5. Hyshka EE, Anderson J, Wong Z-W, Wild TC. Risk behaviours and service needs of marginalized people who use drugs in edmonton’s inner city: Results from the Edmonton Drug Use and Health Survey. Edmonton: University of Alberta School of Public Health; 2016. [Google Scholar]
  6. Jozaghi E, Lampkin H, Andresen MA. Peer-engagement and its role in reducing the risky behavior among crack and methamphetamine smokers of the Downtown Eastside community of Vancouver, Canada. Harm Reduction Journal. 2016;13(19):1–9. doi: 10.1186/s12954-016-0108-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Leonard L, DeRubeis E, Pelude L, Medd E, Birkett N, Seto J. “I inject less as I have easier access to pipes”: Injecting, and sharing of crack-smoking materials, decline as safer crack-smoking resources are distributed. Int J Drug Policy. 2008;19(3):255–264. doi: 10.1016/j.drugpo.2007.02.008. [DOI] [PubMed] [Google Scholar]
  8. Malchy L, Bungay V, Johnson J. Documenting practices and perceptions of 'safer' crack use: A Canadian pilot study. Int J Drug Policy. 2008;19(4):339–341. doi: 10.1016/j.drugpo.2007.06.005. [DOI] [PubMed] [Google Scholar]
  9. McNeil R, Kerr T, Lampkin H, Small W. "We need somewhere to smoke crack": An ethnographic study of an unsanctioned safer smoking room in Vancouver, Canada. Int J Drug Policy. 2015;26(7):645–652. doi: 10.1016/j.drugpo.2015.01.015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Pijl EM, Bourque S, May J, Manning J, Lethbridge ARCHES. Risk behaviours and service needs of marginalized people who use drugs in lethbridge: Results from the Alberta Drug Use and Health Survey. Lethbridge: University of Lethbridge; 2017. [Google Scholar]
  11. Riley AL, Kearns D, Hargrave S, Davidson T. Cocaine increases permeability of blood-brain-barrier in the hippocampus and striatum: Implications for drug use and abuse. Drug & Alcohol Dependence. 2017;171:e177–e177. doi: 10.1016/j.drugalcdep.2016.08.485. [DOI] [Google Scholar]
  12. Sajja RK, Rahman S, Cucullo L. Drugs of abuse and blood-brain barrier endothelial dysfunction: A focus on the role of oxidative stress. J Cereb Blood Flow Metab. 2016;36(3):539–554. doi: 10.1177/0271678X15616978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Shannon K, Ishida T, Morgan R, Bear A, Oleson M, Kerr T, Tyndall MW. Potential community and public health impacts of medically supervised safer smoking facilities for crack cocaine users. Harm Reduct J. 2006;3:1. doi: 10.1186/1477-7517-3-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Strike C, Rotondi NK, Watson TM, Kolla G, Bayoumi AM. Public opinions about supervised smoking facilities for crack cocaine and other stimulants. Substance Abuse Treatment, Prevention, and Policy. 2016;11:8. doi: 10.1186/s13011-016-0052-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Voon P, Ti L, Dong H, Milloy M-J, Wood E, Kerr T, Hayashi K. Risky and rushed public crack cocaine smoking: The potential for supervised inhalation facilities. BMC Public Health. 2016;16:476. doi: 10.1186/s12889-016-3137-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Watson TM, Strike C, Kolla G, Penn R, Jairam J, Hopkins S, Bayoumi AM. Design considerations for supervised consumption facilities (SCFs): Preferences for facilities where people can inject and smoke drugs. Int J Drug Policy. 2013;24(2):156–163. doi: 10.1016/j.drugpo.2012.09.003. [DOI] [PubMed] [Google Scholar]

Articles from Canadian Journal of Public Health = Revue Canadienne de Santé Publique are provided here courtesy of Springer

RESOURCES